Opinion|Videos|July 22, 2024
Biologic Therapies for Hidradenitis Suppurativa
Author(s)Vivian Shi, MD, FAAD
A dermatologist outlines the role for biologic therapies in the hidradenitis suppurativa treatment landscape and discusses the importance of early intervention.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What is the “window of opportunity” with anti-inflammatory treatments in HS and why is early intervention with biologic therapies so imperative?
- Which biologic therapies are currently used in HS and what are the important patient considerations you consider before utilizing these?
Advertisement
Related to this article
Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.
Vitamin K shot refusals rose 77% from 2017 to 2024. Experts break down the drivers, risks, and how clinicians and payers should respond in 5 FAQs.
Oral GLP-1s, Medicare access, and lingering weight bias are reshaping obesity care, says NYU Langone's Holly Lofton, MD.
Activated memory B cells were already enriched at treatment end in the 5 of 21 patients who later cleared HBsAg
Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.
Specialty pharmacy leaders will gather in National Harbor for inSPire2026, tackling cell and gene therapy access, AI, and high-cost drug pricing.
Debra Patt, MD, PhD, MBA, MPH, discusses AI adoption, administrative burden, and strategies to streamline prior authorization in oncology.
ERS spotlights AI lung disease detection; employer cancer benefits; outpatient CAR T; tafasitamab response similar across races; HFpEF missed at referral.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
3
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
4
Which Antibiotics Raise C. Diff Risk Most? Jason Pogue, PharmD
5